GE医疗 总裁兼首席执行官Peter Arduini表示："Jeannette是一位经验丰富的领导者，她在医疗行业的上市公司中拥有丰富且深厚的经验。欢迎她加入公 司，我们相信她将会推动部门向前发展，并实现GE医疗的精准医疗战略。" 报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 2025年4月9日，GE医疗集团官网发布通知， 任命Jeannette Bankes为患者护理解决方案部门总裁兼首席执行官，并将于2025年5月1日上任。此前担任这 一职务的 Tom Westrick已在集团工作20多年，即将退休。 # 通知详情 个人履历 Jeannette Bankes 拥有三十年的全球工作经验，涵盖产品管理、市场营销、销售、法规事务、医学事务以及运营和制造等领域。加入GE医疗之前，她曾在 爱尔康公司 工作， 担任 全球业务高级副总裁，负责全球外科、视力保健和眼部健康业务的产品开发、产品组合管理和产品商业化。 除此之外，她 曾在 波士顿科学公司（Boston Scientific） 和 默克公司（Merck ...

Company Overview - Alcon Inc. has launched the Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in the U.S., utilizing ENLIGHTEN NXT Optical technology for superior light utilization and minimal light scatter [1][5] - The company has a market capitalization of $45.76 billion and has consistently beaten earnings expectations over the last four quarters, with an average surprise of 5.92% [4] Product Details - The Clareon PanOptix Pro is designed to enhance near and intermediate vision, offering a range of powers from +6.0 to +34.0 diopters, and includes features for blue light and ultraviolet filtering [6] - The lens is expected to recover 50% of light lost to scatter, improving visual clarity post-cataract surgery [5] Market Position and Trends - Alcon's Surgical segment is benefiting from a diverse product portfolio and strong demand for presbyopia-correcting IOLs, maintaining a leading market share [3] - Following the product launch, Alcon's stock experienced a slight decline of 0.1%, but has seen a 10.5% increase over the past year, outperforming the industry [2] Industry Prospects - The global intraocular lens market was valued at $4.0 billion in 2022 and is projected to grow at a compound annual growth rate of 6.3%, reaching $6.0 billion by 2029, driven by an increase in cataract surgeries and an aging population [10] Recent Developments - Alcon's Clareon Vivity IOL received CE Mark approval, and the company has entered an agreement to acquire LENSAR, enhancing its capabilities in advanced laser solutions for cataract treatment [11][12] - The PanOptix Pro will be available in select U.S. practices, with broader availability expected in May and additional markets rolling out by late 2025 [7][8]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $700,000, reflecting ongoing progress in partner programs [25] - Research and development expenses increased to $18.4 million from $12.3 million in the prior year, driven by advancements in internal programs [25] - Selling, general and administrative expenses decreased to $8.8 million from $9.3 million in the prior year [25] - Cash, cash equivalents, and short-term investments at year-end were $112.4 million, down from $127.1 million as of September 30, 2024 [26] Business Line Data and Key Metrics Changes - The company added four new partners in 2024, including collaborations with Alcon and INVIDX [19][20] - ABS-201, targeting androgenic alopecia, is positioned as a potential flagship asset with a significant market opportunity [14][15] - ABS-101 showed promising preclinical data, indicating lower ADA development risk compared to competitors [17] Market Data and Key Metrics Changes - The market for androgenic alopecia is substantial, with approximately 80 million people affected in the U.S. alone [14] - The company is focusing on developing therapeutics for unmet needs in various indications, including immuno-oncology and inflammation [20] Company Strategy and Development Direction - The company aims to develop ABS-201 internally through later-stage clinical development to retain maximum value [15] - A strategic collaboration with AMD was announced, involving a $20 million investment to enhance computational capabilities for drug design [11][26] - The business model has evolved to focus on high-quality, high-value therapeutic programs rather than merely the number of partnerships [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute across the portfolio of programs and highlighted the potential of ABS-201 and ABS-101 [29] - The company anticipates becoming a clinical-stage biotech with ABS-101 entering the clinic in 2025 and ABS-201 expected to follow in early 2026 [24][29] - Management emphasized the importance of partnerships that can provide significant upfront payments and extend cash runway non-dilutively [39] Other Important Information - The company is leveraging its AI models to create novel therapeutic candidates and improve the accuracy of drug design [85][86] - The partnership with Caltech and the Gates Foundation focuses on developing a universal neutralizing HIV antibody [71] Q&A Session Summary Question: Plans for additional preclinical studies for ABS-101 and ABS-201 - Management confirmed that additional preclinical data for ABS-101 will be disclosed at a scientific conference, and ABS-201 is in the IND enabling phase with data to be shared as well [33][34] Question: Updates on partnership programs and guidance - Management indicated a focus on securing a large pharma partnership and emphasized the importance of transactions that provide significant upfront payments [39][40] Question: Design and endpoints for the planned Phase 1 study of ABS-201 - The Phase 1 study will start with a SAD study followed by a MAD study, focusing on well-accepted endpoints for measuring hair density [43][44] Question: Competitive positioning of anti-TL1A assay - Management acknowledged impressive data from competitors but highlighted potential advantages in dosing and efficacy for their anti-TL1A program [78] Question: Progress on the HIV program and partnership structure - The HIV program is funded by the Gates Foundation, and updates will be provided as preclinical data becomes available [71]

Core Insights - Alcon Inc. is experiencing strong market share gains driven by its innovative product pipeline and focus on research, despite facing challenges from geopolitical pressures and a competitive landscape [1] Group 1: Business Performance - The Surgical segment reported a 5% year-over-year revenue increase in Q4 2024, primarily due to strong international demand for advanced intraocular lenses and equipment [2] - In Vision Care, Alcon is achieving solid growth through strong sales of contact lenses and ocular health products, positioning itself as one of the fastest-growing companies in the sector [3] - Ocular Health continues to perform well, with the Systane family of artificial tears contributing to growth, and the stock has gained 8.4% year-to-date compared to the industry's 4.9% rise [4] Group 2: Challenges and Concerns - Alcon is facing inflationary pressures in electronic components, freight, labor, and materials, which are impacting margins, with net sales costs up 4.2% year-over-year in Q4 [5] - The company is encountering supply chain challenges, particularly with microchips and plastics, which are expected to persist into 2025 [5] - The ophthalmology industry is highly competitive, with Alcon facing competition from both large manufacturers and smaller specialized companies, as well as alternative medical therapies [6] - In the vision care segment, increased competition from Asian contact lens manufacturers is posing significant threats, with a shift in demand towards daily lenses and advanced materials [7]

Financial Data and Key Metrics Changes - Alcon reported sales of $9.8 billion for 2024, with a market sales growth of 6% [8] - Core diluted EPS increased by 16% to $3.05, and free cash flow reached a record $1.6 billion [8][30] - Fourth quarter sales were $2.5 billion, up 6% year-over-year, driven by innovative contact lens portfolio and consumables [30] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 5% year-over-year to $1.4 billion, with implantable sales at $456 million, up 2% [31] - Vision Care sales for the fourth quarter were $1.1 billion, up 7%, with contact lens sales rising 11% to $638 million [33] - Ocular health sales were $416 million, up 2% year-over-year, with strong performance from eyedrops, particularly SYSTANE [34] Market Data and Key Metrics Changes - Global cataract procedures grew approximately mid-single-digits, with global ATIOL penetration up 180 basis points year-over-year [27] - The retail contact lens market was estimated to be up mid-single-digits, driven mainly by pricing and lens trade-up [28] Company Strategy and Development Direction - Alcon is focusing on innovation, operational excellence, and speed to market, with a rich product pipeline set for launch [9][10] - Upcoming product launches include UNITY VCS in surgical equipment and PanOptix Pro in IOLs, aimed at enhancing efficiency and patient outcomes [13][17] - The company is also investing in over-the-counter assets like SYSTANE and expanding its pharmaceutical pipeline [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the global eye care market, expecting a growth rate of 4% to 5% [38] - For 2025, Alcon anticipates revenue between $10.2 billion and $10.4 billion, with a constant currency growth rate of 6% to 8% [38][41] - The company expects operating margin to be between 21% and 22%, reflecting planned investments in new product launches [39][41] Other Important Information - The Board of Directors proposed an increase in the dividend to CHF0.28 per share and authorized a share repurchase program of up to $750 million [43] - Alcon's leadership team and organizational structure have been realigned to enhance focus on innovation and operational efficiency [9] Q&A Session Summary Question: US ATIOL business performance and competitive impact - Management noted small growth in the US ATIOL market, with competitive trialing affecting year-on-year changes [49] Question: Margin expectations for the first half of 2025 - Management expects some margin expansion in the back half of the first half of 2025, but not significant in Q1 due to investments [54] Question: Updates on US ATIOL market share - Management indicated stable global share with significant growth in China, but some share loss in the US due to competition [58] Question: Price dynamics and volume growth in contact lenses - Management stated that about a third of growth came from price, with expectations for steady volume growth in the contact lens segment [68] Question: Guidance for revenue growth in 2025 - Management expects revenue growth to be at the low-end of guidance in the first half, with acceleration in the second half due to new product launches [80] Question: Feedback on UNITY equipment and growth expectations - Management expressed optimism about the equipment business, expecting strong growth driven by new product launches in the back half of the year [84] Question: IOL market momentum in China - Management reported significant share gains in China, with positive momentum for products like Vivity [92] Question: Interest in drug delivery technologies in IOL market - Management acknowledged awareness of drug delivery technologies but indicated a cautious approach, preferring to observe market developments [100]